Table 3.

Univariate analyses of certain factors for bDFS in 70 patients treated with IMRT plus regional hyperthermia.

Variation	Patients (n)	5-y (%)	p (Log-Rank Test)	Hazard Ratio * (95% Confidence Interval)
T stage
T1–T2	56	89.0	0.8403	0.802 (0.094–6.869)
T3a	14	92.9
Gleason score
≤8	42	91.2	0.5298	0.602 (0.121–2.984)
≥9	28	87.7
Pretreatment PSA (ng/mL)
≤20	39	89.7	0.784	0.800 (0.161–3.964)
>20	31	89.7
Total ADT (months)
≤10	42	86.3	0.2986	0.338 (0.039–2.894)
>10	28	96.3
Hyperthermia
CEM43T90 (min)
≤7	31	81.5	0.0316	0.134 (0.016–1.152)
>7	39	96.4

* Hazard ratio and 95% confidence interval were calculated using the Wald test.